Prolongation of tumour volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy.

Sabra, Mona M; Sherman, Eric; Tuttle, Robert Michael

Sabra, Mona M; Sherman, Eric; Tuttle, Robert Michael.

Afiliação

Sabra MM; Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill-Cornell College of Medicine, New York, New York.
Sherman E; Head and Neck Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill-Cornell College of Medicine, New York, New York.
Tuttle RM; Endocrinology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill-Cornell College of Medicine, New York, New York.

Clin Endocrinol (Oxf) ; 90(4): 617-622, 2019 04.

Article em En | MEDLINE | ID: mdl-30706513

Assuntos

Neoplasias da Glândula Tireoide/patologia; Adulto; Idoso; Idoso de 80 Anos ou mais; Feminino; Humanos; Radioisótopos do Iodo; Masculino; Pessoa de Meia-Idade; Terapia de Alvo Molecular; Estudos Retrospectivos; Neoplasias da Glândula Tireoide/mortalidade; Neoplasias da Glândula Tireoide/terapia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Glândula Tireoide Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google